MetLife Investment Advisors LLC acquired a new position in shares of Becton Dickinson and Co (NYSE:BDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 81,989 shares of the medical instruments supplier’s stock, valued at approximately $17,551,000.
A number of other hedge funds have also recently modified their holdings of BDX. New York State Common Retirement Fund grew its position in Becton Dickinson and by 3.5% during the 3rd quarter. New York State Common Retirement Fund now owns 968,870 shares of the medical instruments supplier’s stock worth $189,850,000 after acquiring an additional 32,600 shares during the last quarter. Commonwealth Equity Services Inc grew its position in shares of Becton Dickinson and by 6.0% in the 3rd quarter. Commonwealth Equity Services Inc now owns 55,261 shares of the medical instruments supplier’s stock valued at $10,828,000 after buying an additional 3,150 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Becton Dickinson and by 90.3% in the 3rd quarter. SG Americas Securities LLC now owns 76,116 shares of the medical instruments supplier’s stock valued at $14,915,000 after buying an additional 36,118 shares during the last quarter. Buckingham Capital Management Inc. grew its position in shares of Becton Dickinson and by 6.8% in the 3rd quarter. Buckingham Capital Management Inc. now owns 13,895 shares of the medical instruments supplier’s stock valued at $2,723,000 after buying an additional 883 shares during the last quarter. Finally, Novare Capital Management LLC grew its position in shares of Becton Dickinson and by 31.7% in the 3rd quarter. Novare Capital Management LLC now owns 34,505 shares of the medical instruments supplier’s stock valued at $6,761,000 after buying an additional 8,311 shares during the last quarter. Institutional investors and hedge funds own 83.35% of the company’s stock.
In related news, VP John E. Gallagher sold 5,346 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the transaction, the vice president now directly owns 9,391 shares of the company’s stock, valued at approximately $2,123,117.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total value of $426,079.00. Following the transaction, the executive vice president now directly owns 15,387 shares in the company, valued at $3,492,849. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 281,108 shares of company stock worth $61,321,396. 1.00% of the stock is owned by company insiders.
Becton Dickinson and stock opened at $223.27 on Monday. The stock has a market capitalization of $59,443.96, a PE ratio of 170.44, a PEG ratio of 1.62 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the prior year, the business earned $2.33 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. sell-side analysts predict that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.34%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
A number of equities research analysts have commented on the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $260.00 price target (up previously from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Morgan Stanley upped their price target on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets assumed coverage on Becton Dickinson and in a research report on Monday, March 5th. They issued a “market perform” rating and a $249.00 price target on the stock. Six research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $238.00.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/19/metlife-investment-advisors-llc-takes-position-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.